Holen Sie sich die Stockscreener-App
2.85
4.68%
-0.14
Handel nachbörslich:
2.85
Schlusskurs vom Vortag:
$2.99
Offen:
$3
24-Stunden-Volumen:
156.69K
Relative Volume:
0.65
Marktkapitalisierung:
$79.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.14M
KGV:
-3.0978
EPS:
-0.92
Netto-Cashflow:
$-12.64M
1W Leistung:
+3.26%
1M Leistung:
+27.23%
6M Leistung:
+43.94%
1J Leistung:
+30.14%
1-Tages-Spanne:
$2.80
$3.04
1-Wochen-Bereich:
$2.76
$3.12
52-Wochen-Spanne:
$1.26
$3.12
Immix Biopharma Inc Stock (IMMX) Company Profile
Firmenname
Immix Biopharma Inc
Sektor
Branche
Telefon
(888) 958-1084
Adresse
11400 WEST OLYMPIC BLVD., LOS ANGELES
Vergleichen Sie IMMX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
2.85 | 76.94M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
What drives Immix Biopharma Inc. stock priceTremendous wealth creation - jammulinksnews.com
What analysts say about Immix Biopharma Inc. stockExceptional earning trajectories - jammulinksnews.com
Is Immix Biopharma Inc. a good long term investmentRecord-setting profit potential - jammulinksnews.com
Immix Biopharma Inc. Stock Analysis and ForecastFree Capital Growth Strategies - jammulinksnews.com
What makes Immix Biopharma Inc. stock price move sharplyFree AI-Powered Stock Predictions - Newser
Why Immix Biopharma Inc. stock attracts strong analyst attentionHigh Yield Opportunities - Newser
How Immix Biopharma Inc. stock performs during market volatilityBreakout Level Watch - Newser
ImmixBio reports no neurotoxicity in CAR-T therapy for AL amyloidosis - Investing.com Nigeria
ImmixBio reports no neurotoxicity in CAR-T therapy for AL amyloidosis By Investing.com - Investing.com South Africa
Immix Biopharma Says NXC-201 Safety Profile Shows Absence of Neurotoxicity in Low-Volume Disease - MarketScreener
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion - MarketScreener
Immix Biopharma Reports Class-Leading Safety Profile for CAR-T NXC-201 in Low-Volume AL Amyloidosis, On Track for BLA Submission - Nasdaq
Revolutionary CAR-T Safety Data: IMMX Reports Zero Neurotoxicity in Rare Disease Treatment - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Stock Price Up 1.5% – Here’s Why - Defense World
Immix Biopharma stock advances as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Nigeria
Immix Biopharma stock advances as H.C. Wainwright reiterates Buy rating - Investing.com
Immix Biopharma Expands NEXICART-2 Trial Sites Nationwide, Progressing Towards Biologics License Application for Cell Therapy in AL Amyloidosis - Nasdaq
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis - GlobeNewswire
Breakthrough Cell Therapy for AL Amyloidosis Accelerates Toward FDA Approval with 18 Trial Sites - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Upgraded by Wall Street Zen to Hold Rating - Defense World
Immix Biopharma Holds Annual Meeting, Elects Directors - TipRanks
Immix Biopharma CEO Rachman buys $4998 in shares - Investing.com
Jane Street Group LLC Invests $39,000 in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial - MSN
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Q3 EPS Estimates for Immix Biopharma Raised by HC Wainwright - Defense World
Immix Biopharma Attends FDA CEO Forum in Washington DC - GlobeNewswire
ImmixBio Joins Elite Pharma Leaders at FDA Commissioner's Strategic Forum on Drug Development - Stock Titan
Immix Biopharma — ASCO/KOL event reaffirms NXC-201’s potential - Smartkarma
HC Wainwright Comments on Immix Biopharma Q1 Earnings - Defense World
Finanzdaten der Immix Biopharma Inc-Aktie (IMMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):